To learn if the study drug golidocitinib given alone or in combination with the standard drug combination therapy called CHOP can help to control PTCL.
Provision of a signed and dated, written informed consent form prior to any study specific procedures, sampling, and analyses.
Submission of the tumor block or unstained slides from an excisional or core biopsy from nodal or extra-nodal lymphoma tissue (archived or newly obtained sample) is required for retrospective central confirmation of tumor histological subtype.
Aged ≥ 18 years old.
Participants must exhibit Eastern Cooperative Oncology Group (ECOG) performance status 0-2 with no deterioration over the previous 2 weeks.
Any investigational anti-cancer agents or anti-cancer study drugs from a previous clinical study.
Any cytotoxic chemotherapy from a previous treatment regimen.
Corticosteroids at dosages equivalent to prednisone > 40 mg/day within 7 days of the start of the study treatment.
Major surgery procedure (excluding placement of vascular access), or significant traumatic injury within 4 weeks of the first dose of study treatment, or have an anticipated need for major surgery during the study.